Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scynexis Prepares For NDA Filing With Second Phase III Success In VVC

Executive Summary

Novel antifungal ibrexafungerp, a first-in-class triterpenoid, demonstrates ability to clear vulvovaginal candidiasis infections in second pivotal study; firm also looks to demonstrate efficacy in recurrent infections.

You may also be interested in...



Scynexis Data Show Brexafemme Prevents VVC Recurrence

Phase III data showed that the first-in-class oral antifungal can prevent recurrence of vaginal yeast infections, a potentially valuable label addition to the current indication for acute treatment.

Scynexis’s Brexafemme Label-Expansion Plan Focused On Invasive Candidiasis

Scynexis sees a $300m-$400m commercial opportunity for the supplemental indication. A new therapeutic option is needed for oral step-down therapy because many Candida infections are resistant to oral fluconazole.

Scynexis Prepares To Launch Brexafemme In Vaginal Yeast Infections, Priced At $475

The first-in-class, novel antifungal for vaginal yeast infections will enter a genericized market, but also one with strong demand for better therapeutic options.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel